Litcius/Paper detail

Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT)

Klara Kvorning Ternov, Jens Sønksen, Mikkel Fode, Henriette Lindberg, Caroline Kistorp, Rasmus Bisbjerg, Jens Faber, Tobias Wirenfeldt Klausen, Ganesh S. Palapattu, Peter Busch Østergren

2022European Journal of Cancer19 citationsDOI

Topics & Concepts

Abiraterone acetateEnzalutamideProstate cancerMedicinePrednisoneOncologyInternal medicineQuality of life (healthcare)CastrationRandomized controlled trialClinical trialUrologyCancerAndrogen deprivation therapyHormoneNursingAndrogen receptorProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments
Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT) | Litcius